Delivery Order SPE2DB25D3404-SPE2DB25FULTN

Award Date 1/27/25
Potential Completion Date 1/28/25
Potential Value $1.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Insulin Glargine-yfgn U100 Pen 3ML, a type of insulin medication, with a ceiling value of $60,512.43 and a completion date of January 6, 2025. The contract is structured as a firm fixed-price delivery order and is not designated as a set-aside. AmerisourceBergen holds a larger...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Insulin Glargine-yfgn U100 Pen 3ML, a critical medical commodity, over a period ending on January 21, 2025. The contract has a firm fixed price ceiling value of $9,744.82 and is designated as a delivery order, without any set-aside requirements. AmerisourceBergen holds a significant...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Insulin Glargine-yfgn U100 Pen 3ML. The contract has a ceiling value of $2,626.00 and is a firm fixed price delivery order with a completion date of January 15, 2025. The contract is not designated as a set-aside. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of Insulin Glargine-yfgn U100 pens, with a ceiling value of $2,250.94 and a period of performance through January 16, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and...
This is a $17,179.01 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of 4565372242 Insulin Glargine-yfgn U100 Pen 3ML. The contract has an ultimate completion date of August 8, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide insulin glargine-yfgn U100 pens. The contract has a ceiling value of $1,872.71 and a performance period through March 29, 2024. Amerisourcebergen Drug Corp is also the prime contractor on a larger indefinite delivery contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999.00...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a global pharmaceutical sourcing and distribution company. The contract is for the supply of insulin glargine-yfgn U100 pens, with a ceiling value of $1,922.20 and a period of performance through March 22, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,002.80, is for the supply of insulin glargine-yfgn U100 vials (10 mL) to support military and federal healthcare programs. The contract is a firm-fixed-price delivery order with an ultimate completion date of January 14, 2025. AmerisourceBergen holds a significant Indefinite Delivery...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $42,359.34 firm fixed-price contract is for the provision of Insulin Glargine-yfgn U100 Pen 3ML. The award is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary contracting vehicle for AmerisourceBergen to supply a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division. The contract is for the supply of insulin glargine-yfgn U100 pens, with a ceiling value of $3,954.24 and a performance period ending May 1, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00 through December 2025, which serves as the primary vehicle for the company to...
  • SPE2DB25D3404
    Indefinite Delivery Contract
  • SPE2DB25D3404-SPE2DB25FULTN
    Delivery Order

This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Insulin Glargine-yfgn U100 Pen 3ML. The contract has a Ceiling Value of $1,575.60 and runs through January 28, 2025. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not indicate any set-aside designation, suggesting open competition.

Generated 5/4/25, 12:54 AM